Developing vaccines based on cutting-edge Toll-Like Receptor (TLR) biology.
Ongoing Studies
We have a number of ongoing post marketing and investigational studies.
DV2-HBV-25 (Post-marketing Study for Acute Myocardial Infarction Events)
DV2-HBV-26 (Post-marketing Study for Immune-Mediated, Herpes Zoster, and Anaphylaxis Events)
DV2-HBV-27 (Pregnancy Registry)
DV2-HBV-24 (End-Stage Renal Disease)
Partnership
Transforming the treatment of life-threatening diseases requires a science-driven approach, a dynamic team, and constant innovation. If you are of the same mindset and would like to collaborate with Dynavax, contact our business development department.